- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04917393
Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive (MODUS)
16. juni 2022 oppdatert av: Metavention
Multi-Organ Denervation to RedUce Sympathetic Drive, Multi-Center, Prospective Feasibility Study - The MODUS ON MED Study
The objective of the study is to evaluate the safety of multi-organ denervation using the Integrated Radio Frequency (iRF) Denervation System.
and to understand any potential improvement in hypertension and glycemic control.
Studieoversikt
Status
Rekruttering
Intervensjon / Behandling
Detaljert beskrivelse
This study is a prospective, single-arm, multi-center, sham contollred trial to evaluate the initial safety and performance of multi-organ denervation for the treatment of hypertension and type 2 diabetes.
Studietype
Intervensjonell
Registrering (Forventet)
45
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Adam Ahlstrom
- Telefonnummer: 1-612-814-8208
- E-post: aahlstrom@metavention.com
Studiesteder
-
-
-
Tbilisi, Georgia, 0112
- Rekruttering
- Israeli-Georgian Medical Research Clinic Helsicore
-
Tbilisi, Georgia, 0159
- Rekruttering
- Tbilisi Heart and Vascular Clinic
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 80 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 and ≤ 80 years old
- Office systolic blood pressure (SBP) ≥ 135 mmHg or on a stable dose of antihypertensive medication(s) for at least 30 days
- Documented daytime systolic ambulatory blood pressure (ABP) ≥ 135 and < 175 mmHg
- HbA1c ≥7.5% - ≤11.0% on a stable dose of antidiabetic medication(s) for at least 90 days
Waist circumference ≥ 102 cm (male) and ≥ 88 cm (female)
Exclusion Criteria:
Renal artery (RA) anatomy on either side OR common hepatic artery (CHA) anatomy, ineligible for treatment including the following:
- CHA OR RA artery diameter < 4.0 mm or > 7.0 mm
- CHA or RA length that does not allow adequate landing zone for at least one iRF balloon placement and treatment
- Only one functioning kidney
- Presence of abnormal kidney tumors
- CHA or RA with aneurysm
- Pre-existing stent or history of angioplasty in target arteries
- Fibromuscular dysplasia of the CHA or renal arteries
- Presence of CHA OR RA diameter stenosis >30%
- Individual lacks appropriate arterial anatomy for treatment or for maneuvering of the device from the femoral artery to the target location(s)
- Prior renal denervation procedure
- Type 1 diabetes mellitus
- Use of insulin within 90 days prior to Index Procedure
- eGFR < 45 mL/min per 1.73 m2
- One or more documented severe hypertensive crisis (persistent or elevated hypertension > 180 mmHg accompanied by clinical symptoms) in the 90 days prior to Index Procedure
- One or more documented hyperglycemia episodes (requiring hospitalization) in the 90 days prior to Index Procedure
- One or more Severe hypoglycemic events (severe cognitive impairment requiring external assistance for recovery) in the 90 days prior to Index Procedure
- Evidence of active infection within 7 days prior to Index Procedure
- Documented history of chronic active inflammatory bowel disorders such as Crohn's disease or ulcerative colitis
- Any history of cerebrovascular event (e.g., stroke, transient ischemic event, and cerebrovascular accident) within 6 months prior to Index Procedure
- Myocardial infarction within 6 months of Index Procedure
- Heart failure (New York Heart Association [NYHA] Class III-IV) at time of consent.
- Documented confirmed episode(s) of stable or unstable angina within 6 months prior to Index Procedure
- Documented history of persistent or permanent atrial tachyarrhythmia
- Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
- Night shift workers
- Chronic regular use (e.g., daily use) of NSAIDs for 6 months or greater. Aspirin therapy is allowed.
- Active implantable medical device (e.g., ICD or CRT-D, neuromodulator/spinal stimulator, baroreflex stimulator)
- Known Primary pulmonary hypertension (HTN) (> 60 mmHg pulmonary artery or right ventricular systolic pressure)
- Individual has known pheochromocytoma, Cushing syndrome, primary hyperaldosteronism, coarctation of the aorta, untreated hyperthyroidism, untreated hypothyroidism, or primary hyperparathyroidism. (Note: Treated hyperthyroidism and treated hypothyroidism are permissible.)
- A history of bariatric surgery, baroreflex activation therapy, or liver transplant, or these procedures are planned in the 365 days following Index Procedure
- Previous hepatobiliary surgery/intervention that in the opinion of the investigator could preclude the ability to perform denervation of the CHA
- History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy (e.g., orthostatic hypotension attributable to autonomic neuropathy, a diagnosis of gastroparesis, or a clinical history strongly suggestive of delayed gastric emptying)
- ALT or AST greater than 200 U/L
- History or evidence of active / suspected chronic liver or biliary disease including Hepatitis B, Hepatitis C, autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis, Wilson's disease, alpha-1-antitrypsin deficiency, hemochromatosis, drug-induced liver disease, bile duct dilation and obstruction, symptomatic gallstones, liver cancer or liver cirrhosis. Note: subjects with past symptomatic gallstones and a cholecystectomy are not excluded.
- Current or chronic pancreatitis
- Documented contraindication or allergy to contrast medium not amenable to treatment
- Limited life expectancy of < 1 year at the discretion of the investigator
- Any known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or for any reason in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements or whose participation may result in data analysis confounders
- Pregnant, nursing, or planning to become pregnant (documented negative pregnancy test result required documented within a maximum of 7 days before Index Procedure for all women of childbearing potential)
- Concurrent enrollment in any other investigational drug or device trial (participation in noninterventional registries is acceptable)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Enhetens gjennomførbarhet
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Multi-organ denervation
Multi-organ (Hepatic and Renal) denervation with the Integrated Radio Frequency (iRF) Denervation System
|
If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
|
Sham-komparator: Control Arm
Subjects will recieved the sham procedure
|
If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Rate of SADEs
Tidsramme: Index Procedure through 30 days.
|
The primary safety endpoint is the incidence rate of serious adverse device effects (SADEs)
|
Index Procedure through 30 days.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in automated unobserved average office blood pressure
Tidsramme: 90, 180 and 365 days
|
Change from baseline in systolic/diastolic blood pressure as indicated by average automated unobserved office blood pressure
|
90, 180 and 365 days
|
Change in Systolic/Diastolic Blood Pressure - Ambulatory Blood Pressure Monitoring
Tidsramme: 90, 180 and 365 days
|
Change from baseline in systolic/diastolic blood pressure as indicated by ambulatory blood pressure monitoring
|
90, 180 and 365 days
|
Change in Glycemic control - HbA1c
Tidsramme: 90 days, 180 days and 365 days
|
Change from baseline in HbA1c percent
|
90 days, 180 days and 365 days
|
Change in Glycemic control - fasting glucose
Tidsramme: 90 days, 180 days and 365 days
|
Change from baseline in fasting plasma glucose
|
90 days, 180 days and 365 days
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
13. september 2021
Primær fullføring (Forventet)
1. oktober 2022
Studiet fullført (Forventet)
1. oktober 2023
Datoer for studieregistrering
Først innsendt
1. juni 2021
Først innsendt som oppfylte QC-kriteriene
7. juni 2021
Først lagt ut (Faktiske)
8. juni 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
21. juni 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
16. juni 2022
Sist bekreftet
1. juni 2022
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2040
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Ubestemt
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hypertensjon
-
University Hospital of CologneUkjentNAFLD; Hypertensjon, White-Coat Hypertension, Masked HypertensionTyskland
-
Karolinska InstitutetFullførtWhite Coat Hypertension
-
Clinical Hospital Centre ZagrebEuropean Society of HypertensionUkjentWhite Coat Hypertension | Blodtrykk | LivsstilsrisikoreduksjonIsrael, Hellas, Belgia, Tyskland, Armenia, Østerrike, Bulgaria, Kroatia, Tsjekkia, Estland, Italia, Libanon, Litauen, Nederland, Polen, Portugal, Romania, Serbia, Spania, Sverige, Ukraina, Storbritannia
-
Regional Hospital HolstebroFullførtSunn | White Coat Hypertension | Essensiell hypertensjonDanmark
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Aktiv, ikke rekrutterendeWhite Coat Hypertension | Hypertensjon, viktigForente stater
-
University of Alabama at BirminghamTroy UniversityFullførtHypertensjon | Hypertensjon, motstandsdyktig mot konvensjonell terapi | Ukontrollert hypertensjon | Hypertensjon, hvit pelsForente stater
-
PD Dr. Grégoire WuerznerSwiss National Science FoundationFullførtHypertensjon | Overvekt | White Coat Hypertension | Resistent hypertensjonSveits
-
University Hospital, ToursFullførtPTFE-dekkede stenter versus nakne stenter i TIPS (Transjugulær Intra-hepatisk Porto-systemisk shunt)Cirrhotic Portal HypertensionFrankrike
-
Sun Yat-sen UniversityFullførtHepatocellulært karsinom (HCC) | Cirrhotic Portal HypertensionKina
Kliniske studier på iRF System Multi-organ Denervation
-
Medtronic VascularFullførtUkontrollert hypertensjonAustralia, New Zealand
-
Adolfo FontenlaRekruttering
-
MetaventionFullførtDiabetes mellitus, type 2Forente stater
-
MetaventionFullførtHypertensjon | Metabolsk syndromGeorgia
-
Medtronic VascularFullførtHypertensjon | AtrieflimmerForente stater, Tyskland
-
Boston Scientific CorporationAvsluttetMedisin-resistent hypertensjonKina
-
University of AdelaideUkjent
-
Lepu Medical Technology (Beijing) Co., Ltd.Chinese Academy of Medical Sciences, Fuwai HospitalFullførtKardiovaskulære sykdommer | Vaskulære sykdommer | Hypertensjon
-
Renal Dynamics GmbHBiosensors Europe SA; Physio-Logic Ltd. Israel; AmeRuss Clinical Trials LLC...UkjentHypertensjon motstandsdyktig mot konvensjonell terapiIsrael, Belgia, Tyskland, Ungarn, Irland, Polen, Den russiske føderasjonen, Serbia